DOID:3493: Difference between revisions

Revision as of 10:35, 12 September 2014

signet ring cell adenocarcinoma

Namespace:

disease_ontology

Definition:

"An adenocarcinoma that derives_from epithelial cells originating in glandular tissue, which have signet ring appearance." [url:http://en.wikipedia.org/wiki/Signet_ring_cell_carcinoma]

Xrefs:

Expandlinks:

Synonyms:

"Signet ring carcinoma NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:189702009]
"Signet Ring cell adenocarcinoma" EXACT [NCI2004_11_17:C3774]
"Signet ring cell carcinoma" EXACT [SNOMEDCT_2005_07_31:189701002]
"Signet ring cell carcinoma (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:87737001]

Ontology association Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies. link to ontology dataset data

Parents

is_a:	DOID:299(adenocarcinoma)

Children

is a:	FF:10436-106E4 (signet ring carcinoma cell line:Kato III),FF:10483-107A6 (signet ring carcinoma cell line:NUGC-4)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

10436-106E4 (signet ring carcinoma cell line:Kato III)
10483-107A6 (signet ring carcinoma cell line:NUGC-4)

Mouse (Mus musculus)

10436-106E4 (signet ring carcinoma cell line:Kato III)
10483-107A6 (signet ring carcinoma cell line:NUGC-4)

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:3493 (signet ring cell adenocarcinoma), sorted by p-values Analyst: Hideya Kawaji link to source dataset human : data mouse : data

Show entries

Search:

P-value	FFCP	Short description
3.29e-195	FFCP PHASE2:Hg19::chr19:10142131..10142138,-	p@chr19:10142131..10142138, -
3.29e-195	FFCP PHASE1:Hg19::chr9:85678229..85678237,+	p@chr9:85678229..85678237, +
3.29e-195	FFCP PHASE1:Hg19::chr19:10142131..10142138,-	p@chr19:10142131..10142138, -
3.29e-195	FFCP PHASE2:Hg19::chr9:85678229..85678237,+	p@chr9:85678229..85678237, +
3.29e-195	FFCP PHASE1:Hg19::chr14:54581722..54581743,-	p@chr14:54581722..54581743, -
3.29e-195	FFCP PHASE2:Hg19::chr19:10142077..10142083,-	p@chr19:10142077..10142083, -
3.29e-195	FFCP PHASE2:Hg19::chr14:54581722..54581743,-	p@chr14:54581722..54581743, -
3.29e-195	FFCP PHASE1:Hg19::chr19:10142077..10142083,-	p@chr19:10142077..10142083, -
4.61e-131	FFCP PHASE2:Hg19::chr19:10142089..10142103,-	p@chr19:10142089..10142103, -
4.61e-131	FFCP PHASE1:Hg19::chr19:10142089..10142103,-	p@chr19:10142089..10142103, -
4.61e-131	FFCP PHASE2:Hg19::chr7:960422..960430,-	p20@ADAP1
4.61e-131	FFCP PHASE1:Hg19::chr7:960534..960548,-	p16@ADAP1
4.61e-131	FFCP PHASE1:Hg19::chr19:5846676..5846682,-	p7@FUT3
4.61e-131	FFCP PHASE2:Hg19::chr7:960534..960548,-	p16@ADAP1
4.61e-131	FFCP PHASE1:Hg19::chr7:960494..960498,-	p19@ADAP1
4.61e-131	FFCP PHASE2:Hg19::chr19:5846676..5846682,-	p7@FUT3
4.61e-131	FFCP PHASE2:Hg19::chr7:960494..960498,-	p19@ADAP1
4.61e-131	FFCP PHASE1:Hg19::chr7:960422..960430,-	p20@ADAP1
8.99e-131	FFCP PHASE1:Hg19::chr19:1753387..1753395,-	p@chr19:1753387..1753395, -
8.99e-131	FFCP PHASE2:Hg19::chr19:1753387..1753395,-	p@chr19:1753387..1753395, -
1.75e-130	FFCP PHASE1:Hg19::chr7:34890932..34890934,+	p@chr7:34890932..34890934, +
1.75e-130	FFCP PHASE2:Hg19::chr7:34890932..34890934,+	p@chr7:34890932..34890934, +
9.38e-99	FFCP PHASE1:Hg19::chr3:5884302..5884308,+	p@chr3:5884302..5884308, +
9.38e-99	FFCP PHASE2:Hg19::chr3:5884302..5884308,+	p@chr3:5884302..5884308, +
1.55e-98	FFCP PHASE1:Hg19::chr10:123378848..123378857,-	p@chr10:123378848..123378857, -
1.55e-98	FFCP PHASE2:Hg19::chr2:28762016..28762055,-	p@chr2:28762016..28762055, -
1.55e-98	FFCP PHASE1:Hg19::chr2:9324969..9324972,-	p@chr2:9324969..9324972, -
1.55e-98	FFCP PHASE1:Hg19::chr17:70417540..70417544,-	p@chr17:70417540..70417544, -
1.55e-98	FFCP PHASE2:Hg19::chr10:123313149..123313152,+	p@chr10:123313149..123313152, +
1.55e-98	FFCP PHASE2:Hg19::chr3:169101687..169101694,-	p@chr3:169101687..169101694, -
1.55e-98	FFCP PHASE1:Hg19::chr10:29217837..29217846,+	p@chr10:29217837..29217846, +
1.55e-98	FFCP PHASE1:Hg19::chr19:1654251..1654268,-	p@chr19:1654251..1654268, -
1.55e-98	FFCP PHASE2:Hg19::chr1:183976888..183976895,-	p@chr1:183976888..183976895, -
1.55e-98	FFCP PHASE1:Hg19::chr3:124209926..124209941,-	p@chr3:124209926..124209941, -
1.55e-98	FFCP PHASE2:Hg19::chr20:61298271..61298272,-	p5@ENST00000411824
1.55e-98	FFCP PHASE1:Hg19::chr10:122520831..122520842,+	p@chr10:122520831..122520842, +
1.55e-98	FFCP PHASE2:Hg19::chr13:74185102..74185107,+	p@chr13:74185102..74185107, +
1.55e-98	FFCP PHASE2:Hg19::chr19:1654223..1654233,-	p@chr19:1654223..1654233, -
1.55e-98	FFCP PHASE2:Hg19::chr10:123378848..123378857,-	p@chr10:123378848..123378857, -
1.55e-98	FFCP PHASE1:Hg19::chr13:74185102..74185107,+	p@chr13:74185102..74185107, +
1.55e-98	FFCP PHASE2:Hg19::chr17:74459187..74459193,-	p@chr17:74459187..74459193, -
1.55e-98	FFCP PHASE2:Hg19::chr2:121082746..121082759,-	p@chr2:121082746..121082759, -
1.55e-98	FFCP PHASE2:Hg19::chr17:56492937..56492946,-	p11@RNF43
1.55e-98	FFCP PHASE1:Hg19::chr20:61316967..61316974,-	p@chr20:61316967..61316974, -
1.55e-98	FFCP PHASE2:Hg19::chr16:85016361..85016372,+	p@chr16:85016361..85016372, +
1.55e-98	FFCP PHASE2:Hg19::chr10:29217837..29217846,+	p@chr10:29217837..29217846, +
1.55e-98	FFCP PHASE1:Hg19::chrX:96374896..96374901,+	p@chrX:96374896..96374901, +
1.55e-98	FFCP PHASE2:Hg19::chr22:49239060..49239068,+	p@chr22:49239060..49239068, +
1.55e-98	FFCP PHASE2:Hg19::chr10:122520831..122520842,+	p@chr10:122520831..122520842, +
1.55e-98	FFCP PHASE1:Hg19::chr20:61298173..61298178,-	p4@ENST00000411824
1.55e-98	FFCP PHASE2:Hg19::chr1:188011911..188011936,+	p@chr1:188011911..188011936, +
1.55e-98	FFCP PHASE1:Hg19::chr6:167684529..167684536,+	p6@UNC93A
1.55e-98	FFCP PHASE1:Hg19::chr12:18400438..18400444,-	p@chr12:18400438..18400444, -
1.55e-98	FFCP PHASE2:Hg19::chr3:142285096..142285107,-	p@chr3:142285096..142285107, -
1.55e-98	FFCP PHASE1:Hg19::chr10:122910650..122910656,+	p@chr10:122910650..122910656, +
1.55e-98	FFCP PHASE1:Hg19::chr5:167545123..167545128,+	p60@ODZ2
1.55e-98	FFCP PHASE2:Hg19::chr1:178009766..178009803,+	p@chr1:178009766..178009803, +
1.55e-98	FFCP PHASE1:Hg19::chr21:25744883..25744889,-	p@chr21:25744883..25744889, -
1.55e-98	FFCP PHASE1:Hg19::chr17:74459348..74459359,-	p@chr17:74459348..74459359, -
1.55e-98	FFCP PHASE1:Hg19::chr3:169101774..169101782,-	p@chr3:169101774..169101782, -
1.55e-98	FFCP PHASE1:Hg19::chr2:37609861..37609884,+	p@chr2:37609861..37609884, +
1.55e-98	FFCP PHASE1:Hg19::chr1:183976829..183976846,-	p@chr1:183976829..183976846, -
1.55e-98	FFCP PHASE2:Hg19::chr5:167545081..167545101,+	p46@ODZ2
1.55e-98	FFCP PHASE2:Hg19::chr6:110282878..110282882,-	p@chr6:110282878..110282882, -
1.55e-98	FFCP PHASE1:Hg19::chr17:50828983..50828988,+	p@chr17:50828983..50828988, +
1.55e-98	FFCP PHASE2:Hg19::chr3:169101737..169101746,-	p@chr3:169101737..169101746, -
1.55e-98	FFCP PHASE2:Hg19::chr10:122910650..122910656,+	p@chr10:122910650..122910656, +
1.55e-98	FFCP PHASE1:Hg19::chr15:42186200..42186205,-	p3@SPTBN5
1.55e-98	FFCP PHASE1:Hg19::chr10:29217861..29217870,+	p@chr10:29217861..29217870, +
1.55e-98	FFCP PHASE2:Hg19::chr2:9324969..9324972,-	p@chr2:9324969..9324972, -
1.55e-98	FFCP PHASE1:Hg19::chr20:61278219..61278228,-	p@chr20:61278219..61278228, -
1.55e-98	FFCP PHASE1:Hg19::chr10:122520854..122520858,+	p@chr10:122520854..122520858, +
1.55e-98	FFCP PHASE2:Hg19::chr19:1654251..1654268,-	p@chr19:1654251..1654268, -
1.55e-98	FFCP PHASE2:Hg19::chr3:124209926..124209941,-	p@chr3:124209926..124209941, -
1.55e-98	FFCP PHASE2:Hg19::chr17:74459285..74459291,-	p@chr17:74459285..74459291, -
1.55e-98	FFCP PHASE1:Hg19::chr22:46406849..46406852,+	p@chr22:46406849..46406852, +
1.55e-98	FFCP PHASE1:Hg19::chr5:499786..499794,-	p@chr5:499786..499794, -
1.55e-98	FFCP PHASE2:Hg19::chr10:29217861..29217870,+	p@chr10:29217861..29217870, +
1.55e-98	FFCP PHASE2:Hg19::chr12:18400438..18400444,-	p@chr12:18400438..18400444, -
1.55e-98	FFCP PHASE2:Hg19::chrX:96374896..96374901,+	p@chrX:96374896..96374901, +
1.55e-98	FFCP PHASE2:Hg19::chr17:51139124..51139129,+	p@chr17:51139124..51139129, +
1.55e-98	FFCP PHASE2:Hg19::chr10:122520854..122520858,+	p@chr10:122520854..122520858, +
1.55e-98	FFCP PHASE1:Hg19::chr20:61298207..61298221,-	p2@ENST00000411824
1.55e-98	FFCP PHASE2:Hg19::chr20:61316967..61316974,-	p@chr20:61316967..61316974, -
1.55e-98	FFCP PHASE2:Hg19::chr17:70619903..70619909,+	p@chr17:70619903..70619909, +
1.55e-98	FFCP PHASE1:Hg19::chr13:97775112..97775117,+	p@chr13:97775112..97775117, +
1.55e-98	FFCP PHASE1:Hg19::chr10:123000012..123000015,+	p@chr10:123000012..123000015, +
1.55e-98	FFCP PHASE1:Hg19::chr17:56492937..56492946,-	p11@RNF43
1.55e-98	FFCP PHASE1:Hg19::chr9:139312981..139312986,+	p4@PMPCA
1.55e-98	FFCP PHASE1:Hg19::chr5:167545165..167545170,+	p61@ODZ2
1.55e-98	FFCP PHASE2:Hg19::chr20:61298173..61298178,-	p4@ENST00000411824
1.55e-98	FFCP PHASE2:Hg19::chr15:42186200..42186205,-	p3@SPTBN5
1.55e-98	FFCP PHASE2:Hg19::chr6:167684529..167684536,+	p6@UNC93A
1.55e-98	FFCP PHASE2:Hg19::chr13:73809919..73809926,+	p@chr13:73809919..73809926, +
1.55e-98	FFCP PHASE1:Hg19::chr1:183976861..183976878,-	p@chr1:183976861..183976878, -
1.55e-98	FFCP PHASE2:Hg19::chr2:37609861..37609884,+	p@chr2:37609861..37609884, +
1.55e-98	FFCP PHASE1:Hg19::chr12:93412598..93412606,-	p@chr12:93412598..93412606, -
1.55e-98	FFCP PHASE2:Hg19::chr19:10142279..10142292,-	p@chr19:10142279..10142292, -
1.55e-98	FFCP PHASE2:Hg19::chr5:167545123..167545128,+	p60@ODZ2
1.55e-98	FFCP PHASE2:Hg19::chr12:93412598..93412606,-	p@chr12:93412598..93412606, -

Showing 1 to 100 of 100 entries

@@ Line 1: / Line 1: @@
 {{DOID
-|id=DOID:3493
+|alt_id=
-|name=signet ring cell adenocarcinoma
-|namespace=disease_ontology
-|def="An adenocarcinoma that derives_from epithelial cells originating in glandular tissue, which have signet ring appearance." [url:http://en.wikipedia.org/wiki/Signet_ring_cell_carcinoma]
-|xref=MSH:D018279;;NCI:C3774;;SNOMEDCT_2010_1_31:189701002;;SNOMEDCT_2010_1_31:189702009;;SNOMEDCT_2010_1_31:87737001;;UMLS_CUI:C0206696
-|is_a=DOID:299
-|synonym="Signet ring carcinoma NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:189702009];;"Signet Ring cell adenocarcinoma" EXACT [NCI2004_11_17:C3774];;"Signet ring cell carcinoma" EXACT [SNOMEDCT_2005_07_31:189701002];;"Signet ring cell carcinoma (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:87737001]
 |comment=
-|alt_id=
-|disjoint_from=
-|union_of=
 |created_by=
-|obo_creation_date=
+|def="An adenocarcinoma that derives_from epithelial cells originating in glandular tissue, which have signet ring appearance." [url:http://en.wikipedia.org/wiki/Signet_ring_cell_carcinoma]
-|subset=
 |derives_from=
 |develops_from=
+|disjoint_from=
 |has_quality=
+|id=DOID:3493
+|is_a=DOID:299
+|is_obsolete=
 |located_in=
+|name=signet ring cell adenocarcinoma
+|namespace=disease_ontology
+|obo_creation_date=
 |part_of=
+|preceded_by=
 |property_value=IAO:0000412 file:/Users/cjm/Dropbox/fantom5/HumanDO.obo
-|is_obsolete=
+|subset=
-|preceded_by=
+|synonym="Signet ring carcinoma NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:189702009];;"Signet Ring cell adenocarcinoma" EXACT [NCI2004_11_17:C3774];;"Signet ring cell carcinoma" EXACT [SNOMEDCT_2005_07_31:189701002];;"Signet ring cell carcinoma (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:87737001]
+|union_of=
+|xref=MSH:D018279;;NCI:C3774;;SNOMEDCT_2010_1_31:189701002;;SNOMEDCT_2010_1_31:189702009;;SNOMEDCT_2010_1_31:87737001;;UMLS_CUI:C0206696
 }}

Personal tools

DOID:3493: Difference between revisions - resource_browser

Search

Human

Mouse

Rat

Dog

Chicken

Macaque

Cross species

Other

Tools

DOID:3493: Difference between revisions

From FANTOM5_SSTAR

Revision as of 10:35, 12 September 2014

Ontology Tree: Loaded from BioPortal

FF samples

	FAQ
	Mozilla Cavendish skin modified by DaSch for the Web Community Wiki GitHub project page – Report a bug – Skin version: 2.6.0